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Abstract 
Copanlisib is a pan phosphatidylinositol 3-kinase (PI3K) inhibitor approved for follicular lymphoma. In this 
paper, we present the data of development and validation of a high-performance liquid chromatography 
(HPLC) method for the quantitation of copanlisib in mice plasma as per the FDA regulatory guideline. The 
method involves the extraction of copanlisib along with internal standard (IS, enasidenib) from mice plasma 
(100 µL) using ethyl acetate as an extraction solvent. The chromatographic resolution of copanlisib and the IS 
was achieved on a Hypersil Gold C18 column maintained at 40 °C using a binary gradient mobile phase [10 mM 
ammonium formate (pH 4.0) and acetonitrile]. The flow-rate was 0.8 mL/min. For the detection of copanlisib 
and the IS, the photo-diode array detector was set at λmax 310 nm. Copanlisib and the IS eluted at 6.60 and 7.80 
min, respectively with a total run time of 10 min. The calibration curve was linear over a concentration range of 
50 to 5000 ng/mL for copanlisib (r
2
 0.998). The results of intra- and inter-day accuracy and precision studies 
were within the acceptable limits. Copanlisib was stable on bench-top, in auto-sampler, up to three 
freeze/thaw cycle and long-term storage at -80 °C. The application of the validated method was shown in a 
mice pharmacokinetic study. 
©2020 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons 
Attribution license (http://creativecommons.org/licenses/by/4.0/). 
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Introduction 
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases, which play a pivotal role in cell cycle, cellular 
metabolism, apoptosis etc. along with α-serine/threonine-protein kinase (AKT)/mammalian target of 
rapamycin (mTOR) pathway [1]. Abnormal activation of PI3K pathway has been shown to drive 
tumorigenesis [2]. Among three classes of the PI3K enzyme, class I PI3K is linked with malignance and it 
exists in four isoforms: α, β, γ and δ [3,4]. PI3K inhibitors represent a novel class of targeted therapies for 
the treatment of human malignancies [5]. Preclinical and clinical studies demonstrated that inhibition of 
PI3K is an effective therapeutic strategy for lymphomas treatment [6]. Copanlisib (Fig. 1; BAY 80-6946), is a 
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pan-PI3K inhibitor with predominant activity against PI3K-α and PI3K-δ forms, which are expressed in 
malignant B-cells. The IC50 (half-maximal inhibitory concentration) against PI3K α, β, γ and δ isoforms was 
0.5, 3.7, 6.4 and 0.7 nmol/L, respectively [7]. It induces tumor cell death by apoptosis and inhibition of 
proliferation of primary malignant B cell lines. Copanlisib was approved for treatment of follicular 
lymphoma as an intravenous infusion for adults. In clinic, at 0.8 mg/kg (intravenous infusion), copanlisib 
showed promising efficacy in patients with solid tumors and hematological malignancies. Across the dose 
range of 0.1-1.2 mg/kg, it has shown dose proportional increase in Cmax (maximum concentration in 
plasma) and AUC0-t (area under curve from time zero to last measurable time point). Typically, Cmax attained 
between 0.5-1.0 h (Tmax). The human plasma protein binding of copanlisib is ~84 %. Copanlisib was majorly 
metabolized by CYP3A4 (>90 % metabolism) and to some extent by CYP1A1 (~10 % of metabolism) to yield 
M1, an active metabolite, which possess similar potency as copanlisib. The terminal half-life and clearance 
for copanlisib at 0.8 mg/kg were 39.1 h and 18.9 L/h. Copanlisib has high volume of distribution (871 L). Up 
to 50 % of unchanged drug and remaining amount in the form of metabolites is excreted in humans [8].  
 
Figure 1. Structural representation of copanlisib and enasidenib (internal standard, IS) 
Until date, only one bioanalytical method was published for quantification of copanlisib [9]. In the 
reported LC-MS/MS (liquid chromatography coupled with tandem mass spectrometry) method, authors 
used one step liquid-liquid extraction method for mice plasma samples processing. The linearity range was 
3.59-3588 ng/mL. Using an isocratic mobile phase, copanlisib and the internal standard were resolved on a 
HyPurity C18 column having a total run time of 3.0 min.  
Although LC-MS/MS is a powerful tool for the quantitation of drugs in various biological matrices with 
higher sensitivity in short run time, its high cost and maintenance limit its availability for most of the 
hospitals, academic institutes and research laboratories. The lower cost and affordability of the HPLC 
instrument compared to that of LC-MS/MS renders HPLC methods more eligible for wide routine use. 
In clinic, at efficacy dose of 0.8 mg/kg, copanlisib plasma concentrations were ~50 ng/mL at 8 h (both on 
day-1 and day-15) in patients with non-Hodgkin’s lymphoma and advanced solid tumors [10,11]. By 
achieving 50 ng/mL sensitivity for copanlisib on HPLC-UV, we believe our present method can be used in 
hospitals for routine therapeutic drug monitoring of copanlisib. Besides, the proposed method can also be 
in research laboratories for routine pharmacokinetic and/or toxicokinetic studies samples analysis. In order 
to ensure the reliability, reproducibility and sensitivity of the method, the developed analytical method 
was validated for various parameters in accordance with FDA guideline. The validated method was applied 
to investigate the pharmacokinetics of copanlisib post intravenous administration to mice.  
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Materials and methods  
Chemicals and reagents 
Copanlisib (purity: 99.7 %) was obtained from Beijing Yibai Biotechnology Co., Ltd, Beijing, China. 
Enasidenib (purity: 98 %) used as an internal standard (IS) was purchased from Aaron, Shanghai, China. 
Solutol, ethanol and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich, St. Louis, MO, USA. 
HPLC grade acetonitrile and methanol were purchased from J.T. Baker Avantor, PA, USA. Analytical grade 
hydrochloric acid and ammonium formate were purchased from S.D. Fine Chemicals, Mumbai, India. All 
other chemicals and reagents were of analytical grade and used without further purification. The control 
mice K2.EDTA plasma was procured from Animal House, Jubilant Biosys, Bangalore.  
HPLC operating conditions  
Analysis of copanlisib in plasma samples was performed on a Waters 2695 Alliance HPLC system 
(Waters, Milford, USA) equipped with performance PLUS inline degasser along with an auto-sampler, 
column oven and photo diode array (PDA) detector set at max 310 nm. Chromatographic resolution of 
copanlisib and the internal standard (IS) was achieved by injecting 25 µL of the processed sample on a 
Hypersil Gold C18 column (250  4.0 mm, 5 µm; Thermo Scientific, USA) maintained at 40±1 °C using a 
binary gradient mobile phase consisting 10 mM ammonium formate, pH: 4.0 (adjusted with formic acid) 
(solvent A) and acetonitrile (solvent B) delivered at a flow-rate of 0.8 mL/min. Initial eluent composition 
was 90 % A, maintained for 5.0 min, and followed by a linear 0.5 min ramp to 10 % A, which was 
maintained for until 5.5 min. The mobile phase composition returned to 90 % A at 8.0 min. Equilibration 
time was 2.0 min.  
Preparation of stock solutions for copanlisib and the IS 
For the preparation of calibration curve (CC) and quality control (QC) samples, two primary stock 
solutions of copanlisib were made at 1.0 mg/mL in 0.1 N HCl:DMSO (2:98, v/v). Due to copanlisib limited 
solubility in organic solvents we have used 0.1 N HCl. The primary stock solution of the IS (1.0 mg/mL) was 
prepared in DMSO and subsequently diluted with 80% methanol to get work stock at 0.60 μg/mL. The 
primary stock solutions of copanlisib and the IS were stored at -20±5 °C, which were found to be stable for 
50 days.  
Preparation of calibration curve standards and quality control samples  
The first set of primary stock solution of copanlisib was diluted appropriately and subsequently used to 
prepare a calibration curve (CC) standards. The calibration standard samples were made by spiking the 
blank mice plasma (90 µL) with each corresponding working solution of copanlisib (10 µL) thereby yielding 
final concentrations of 50, 100, 500, 750, 1250, 2500, 3750 and 5000 ng/mL.  
For the determination of precision and accuracy, samples were prepared by spiking blank mice plasma 
in bulk with the second working stock solution of copanlisib at appropriate concentrations and 100 L 
aliquots were distributed into different tubes. The QCs prepared were: 50 ng/mL (lower limit of 
quantification quality control; LLOQ QC), 150 ng/mL (low quality control; LQC), 2250 ng/mL (medium 
quality control; MQC) and 3500 ng/mL (high quality control; HQC). All the QCs were stored together at  
-80±10 °C until analysis.  
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Sample preparation  
To an aliquot of 100 µL mice plasma sample, 1.0 mL of ethyl acetate was added and vortex mixed for 3 
min; followed by centrifugation for 5 min at 14,000 rpm in a refrigerated centrifuge (Eppendorf 5424R) 
maintained at 5 °C. The organic layer (800 µL) was separated and evaporated to dryness at 50 °C using a 
gentle stream of nitrogen (Turbovap®, Zymark®, Kopkinton, MA, USA). The residue was reconstituted in 
100 µL of the IS solution (600 ng/mL) and 25 µL was injected onto HPLC system for analysis.  
Validation procedures  
A full validation according to the US FDA guidance was performed for the quantitation of copanlisib in 
mice plasma [12].  
The selectivity of the proposed method was assessed by evaluating the presence of interfering the 
peaks at the retention times of copanlisib and the IS in six different batches of blank mice plasma samples. 
The auto-injector carry over was determined by injecting the highest calibration standard (5.0 µg/mL) 
followed by injection of mice plasma blank samples. Recovery of copanlisib was determined by comparing 
their respective response from QCs (LQC and HQC) after the extraction process against their non-extracted 
samples. Recovery of the IS was determined at 600 ng/mL. Intra- and inter-day accuracy and precision 
were determined at four QC levels [LLOQ QC (50 ng/mL), LQC (150 ng/mL), MQC (2250 ng/mL) and HQC 
(3500 ng/mL)] along with calibration curve (0.05-5.00 μg/mL). Stability (auto-sampler, bench-top, freeze-
thaw and long-term) studies, dilution effect and incurred sample reanalysis (ISR) were also evaluated as per 
regulatory guideline requirement [12]. 
Pharmacokinetic study in mice  
Twelve male Balb/C mice (weight range: 26-28 g) were procured from Vivo Biotech, Hyderabad, India. 
Animal study protocol used in this study was approved by the Institutional Animal Ethics Committee, 
Jubilant Biosys (IAEC/JDC/2019/188R). Mice were housed for a period of seven days having free access to 
feed and water before the pharmacokinetic study. Mice received copanlisib intravenously [2 % 0.1 N HCl, 
10 % DMSO, 10 % Solutol:absolute alcohol (1:1, v/v) and 78 % normal saline; strength: 0.5 mg/mL; dose 
volume: 10 mL/kg] at 5.0 mg/kg as a bolus dose. Blood samples (100 µL) were collected at pre-determined 
time points (0.12, 0.25, 0.5, 1, 2, 4, 8 and 24 h) through retro-orbital plexus (using Micropipettes, 
Drummond Scientific, PA, USA; catalogue number: 1-000-0500) into polypropylene tubes (having K2.EDTA 
as an anti-coagulant). Sparse sampling technique (three mice per time point) was adopted during blood 
collection so that blood loss from each mouse was kept less than 10 % of total blood volume. Plasma was 
harvested by centrifuging the blood using Biofuge (Hereaus, Germany) at 1760 g for 5 min and stored 
frozen at -80±10 °C until analysis. Mice were allowed to access feed 2 h post-dosing. 
Pharmacokinetic analysis 
Pharmacokinetic parameters were calculated by a non-compartmental method using Phoenix 
WinNonlin 8.1 software (Pharsight, Mountain View, CA, USA). Key pharmacokinetic parameters like 
extrapolated plasma drug concentration at time zero following intravenous bolus injection (C0), area under 
the curve from time zero to infinity (AUC0-), volume of distribution (Vd), total body clearance (CL) and half-
life (t½) were determined for copanlisib.  
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Results and discussion  
Method development and optimization 
Several trials were taken with various columns, mobile phase compositions to select the 
chromatographic conditions, which will give a good resolution of copanlisib and the IS from the 
endogenous matrix substances within a suitable run time. Several mobile phases were tried by changing 
the combination of different organic solvents (acetonitrile and methanol) and buffers (eg: formic acid, 
ammonium acetate, phosphate buffer etc.) with altered flow-rates (in the range of 0.60-1.20 mL/min). To 
choose a stationary phase a variety of columns namely X-Terra Phenyl, Atlantis, Hypersil Gold C18 were 
evaluated. Our trials revealed that mobile phase comprising 10 mM ammonium formate (pH 
4.0):acetonitrile delivered in a gradient program at a flow-rate of 0.8 mL/min on Hypersil Gold C18 column 
gave a stable base line with good resolution between copanlisib and the IS with a total run time of 10 min 
with no interference of endogenous plasma peaks. The UV detector was set at λmax 310 nm. For the 
optimized conditions, enasidenib was found to be a suitable internal standard as it exhibited good 
resolution, retention time and UV absorbance intensity (UV λmax 287 nm) at the same wave length of 
copanlisib.  
Method validation 
With protein precipitation technique the recovery of copanlisib and IS was very poor (<40 %). Liquid-
liquid extraction with ethyl acetate gave best results in terms of extraction recovery, reproducibility and 
cleaner samples. The mean ± S.D recovery of copanlisib at LQC and HQC was 83.8 ± 4.51 and 83.9 ± 1.17 %, 
respectively. The recovery of the IS was 99.5 ± 1.33 %. As shown in Fig. 2, both copanlisib and the IS peaks 
were well resolved and no interference at the retention times of copanlisib and the IS from the 
endogenous components of mice. The retention time of copanlisib and the IS was 6.60 and 7.80 min, 
respectively. The calibration curves (n=4) for copanlisib were observed to be linear in the range of 50-5000 
ng/mL. A representative equation for the calibration curves is as follows: y = 0.0005 x + 0.003. A regression 
equation with a weighting factor of 1/X2 of each drug to the IS concentration was found to produce the 
best fit for the concentration-detector response relationship. The correlation coefficients (r2) were more 
than 0.999, indicating an acceptable linearity of our method. The accuracy observed for the mean of back-
calculated concentrations for four calibration curves was within 89.3-109 %; while the precision (%RE) 
values ranged from 0.95-1.05 %. We did not observe any carry-over produced by the highest calibration 
sample on the following injected mice blank plasma extracted sample for copanlisib.  
 
Figure 2. HPLC chromatograms of a 25 µL injection of (a) blank mice plasma (b) blank mice plasma spiked with 
copanlisib (LLOQ: 50 ng/mL) along with the IS (c) a 0.5 h plasma sample showing the peak of copanlisib 
(concentration: 3500 ng/mL) following intravenous administration of copanlisib  to mice at 5.0 mg/kg. 
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Table 1.  Intra- and inter-day precision and accuracy determination of 
copanlisib quality controls in mice plasma 
Accuracy and precision data for 
intra- and inter-day mice plasma 
samples determined for copanlisib 
(from four different batches) at LLOQ 
QC (50 ng/mL), LQC (150 ng/mL), MQC 
(2250 ng/mL) and HQC (3500 ng/mL) 
are presented in Table 1. The intra- and 
inter-day precisions (RSD) were within 
7.59 %, and accuracy (RE) ranged 
between 0.97-1.07 %. The assay values 
on both the occasions (intra- and inter-
day) were found to be within the 
accepted variable limits indicating that 
the present method is reproducible, 
accurate and precise. Table 2 
summarizes the results of stability 
studies conducted for copanlisib in 
mice plasma. The measured 
concentrations for copanlisib at LQC 
(150 ng/mL) and HQC (3500 ng/mL) 
deviated within ±15 % of the nominal 
concentrations in a battery of stability 
tests namely in-injector (16 h), bench-
top (6 h), repeated three freeze/thaw 
cycles and freezer stability at -8010 °C 
for 30 days (Table 2) supported the 
stability of copanlisib at various 
stability conditions. The dilution 
integrity was confirmed for QC samples that exceeded the upper limit of the quantitation (ULOQ) of 
calibration curve (up to 35000 ng/mL). The mean accuracy and precision for 15 times diluted samples were 
found to be less than 7.62 and 6.25 %, respectively, which show the ability to dilute samples up to a 
dilution factor of ten in a linear fashion (Table 2). All the samples selected for ISR met the acceptance 
criteria. The back-calculated accuracy values ranged between 89.2-110 % from the initial assay results as 
shown in Fig. 3 using a Bland-Altman plot. 
Pharmacokinetic study 
Plasma samples collected during pharmacokinetic study were thawed at room temperature and 
processed as mentioned in Sample preparation section. Along with plasma samples, LQC, MQC and HQC 
samples (made in blank plasma) were assayed in duplicate and were distributed among unknown samples 
in the analytical run. Plasma samples showed high concentration above the high calibration standard 
(5.00 µg/mL) were diluted appropriately with mice blank plasma to bring the concentration within linearity 






Measured concentration (ng/mL) 
Mean ± SD RSD Accuracy, % 
Intra-day (Six  replicates at each concentration) 
50.0 
1 49.4 ± 4.76 9.63 98.9 
2 50.8 ± 3.89 7.65 101 
3 54.3 ± 1.35 2.49 108 
4 51.0 ± 3.26 6.53 103 
150 
1 139 ± 1.95 1.39 93.2 
2 151 ± 5.77 3.80 101 
3 146 ± 2.88 1.98 97.3 
4 145 ± 3.46 2.36 97.3 
2250 
1 2155 ± 46.5 2.16 95.8 
2 2120 ± 78.9 3.72 94.2 
3 2297 ± 38.1 1.66 102 
4 2190 ± 54.1 2.50 97.4 
3500 
1 3460 ± 81.2 2.32 112 
2 3507 ± 70.0 2.00 104 
3 3545 ± 53.3 1.50 105 
4 3516 ± 68.1 1.94 107 
Inter-day (Twenty four  replicates at each concentration) 
50.0 
 
51.2 ± 3.91 7.59 103 
150 146 ± 6.22 4.28 97.3 
2250 2190 ± 95.1 4.35 96.9 
3500 3504 ± 72.0 2.06 99.9 
RSD: relative standard deviation (SD  100/Mean) 
RE: relative error (measured value/actual value) 
SD: standard deviation 
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samples should be ±15 % of the nominal concentration values (ii) ≥ 50 % of QC samples per level should be 
±15 % of their nominal concentration values [12].  
















Bench-top (6 h) stability 
150 150 ± 2.72 99.8 1.80 
3500 3548 ± 66.6 101 1.88 
In-injector (16 h) stability 
150 146 ± 4.77 98.0 3.25 
3500 3808 ± 34.0 107 0.89 
Freeze-thaw (3 cycles) 
stability 
150 159 ± 12.3 106 7.70 
3500  3774 ± 107 107 2.84 
Long-term stability at -80°C 
(30 days) 
150 146 ± 3.44 97.3 2.35 
3500 3758 ± 23.0 106 0.61 
*Dilution integrity 2333 2522 ± 403 108 6.25 
RSD: relative standard deviation (SD x 100/Mean) 
RE: relative error (measured value/actual value) 







Figure 3. Bland-Altman plot showing the 




In the mice, plasma concentrations of copanlisib decreased mono-exponentially after intravenous 
administration. Fig. 4 depicts the mean ± S.D plasma concentrations versus time for copanlisib following 
intravenous administration to mice at 5.0 mg/kg. Copanlisib was quantifiable up to 8.0 h post intravenous 
administration to mice. Post intravenous administration, the CL and Vd were found to be 42.1 mL/min/Kg 
and 27.6 L/kg, respectively. The AUC0-∞ attained post intravenous administration was 1978 (ng h)/mL. The 
t½ was 7.58 h. In summary the validated method was sensitive enough to calculate the pharmacokinetic 
parameters of copanlisib.  
Patnaik et al. [10] and Kim et al. [11] reported the plasma concentrations of copanlisib post 
administration at efficacy dose (0.8 mg/kg as 1 h intravenous infusion) to patients with advanced solid 
tumors and non-Hodgkin’s lymphoma. Plasma samples collected in these studies on day-1 and day-15 were 
analyzed using an LC-MS/MS method. We have digitalized the reported plasma concentrations versus time 
plots of copanlisib reported by Patnaik et al. [10] and Kim et al. [11] using DigitizeIt software [13] and found 
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that in both studies copanlisib showed ~50 ng/mL till 8 h. By achieving 50 ng/mL sensitivity for copanlisib 
on HPLC-UV in the present method, we believe our present method can be reliably used in hospitals for 
routine therapeutic drug monitoring of copanlisib. By increasing the plasma volume for sample processing 
and injection volume for HPLC analysis, there is a great possibility that our validated HPLC-UV can be used 






Figure 4. Mean plasma concentration versus 
time profile for copanlisib in mice plasma 




A simple reversed-phase HPLC method for determination of copanlisib in mice plasma has been 
developed and validated. The proposed method is highly specific, accurate, precise and reproducible. All 
the validation parameters were within the acceptable limits for a bioanalytical method as per regulatory 
guideline. This method has been successfully applied to a pharmacokinetic study in mice.  
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